GO
Loading...

FDA Approves GlaxoSmithKline's Oral Drug for Breast Cancer

U.S. health regulators have approved GlaxoSmithKline'spill, Tykerb, for patients with advanced breast cancer after other treatments have failed, the company said on Tuesday.

The drug was cleared for once-daily use in combination with Roche Holding'soral chemotherapy drug Xeloda, or capecitabine, Glaxo said.

Glaxo shares recovered earlier losses after the late afternoon news and closed down 75 cents at $55.25 on the New York Stock Exchange.

Tykerb's approval is expected to launch what Glaxo hopes will be a new era for its oncology business, which is looking to win U.S. clearance for four other cancer medications by 2010.

The Food and Drug Administration approved the drug, also known as lapatinib, for patients with HER-2 positive breast cancer who no longer respond to Roche and Genentech rival product, Herceptin.

Patients should have also tried anthracycline and taxane chemotherapy drugs such as Sanofi-Aventis's, Taxotere, or Bristol-Myers Squibb's, Taxol, the agency added.

Those with the HER-2 positive disease face a more aggressive cancer in which the human epidermal growth factor receptor 2 is over-expressed.

Some analysts expect Glaxo's drug to bring in yearly sales of about $1.35 billion, by 2010. If it were to win approval for more uses, that figure could jump as high as $4 billion a year, according to some estimates.

Contact U.S. News

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    › Learn More

Don't Miss

U.S. Video

  • Mad Money's Jim Cramer breaks down the theme of stealth technology stocks. Cramer says companies that are using proprietary technology to invent entirely new markets and then dominate those markets, fall under that category.

  • Mad Money host Jim Cramer knows it can be difficult to stick with a stock that is going lower but says if you've done the homework, and the story isn't wildly off the rails, then stay long.

  • Mad Money host Jim Cramer, outlines the most common emotionally driven investor mistakes and expresses why it is important to not let skepticism run away with you.